Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Remsima is a brand name for the biologic medication infliximab, which is widely used in the treatment of various inflammatory disorders. This medication belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. Remsima specifically targets and neutralizes the TNF-alpha protein in the body, which plays a significant role in causing inflammation and immune-system related diseases.
Remsima is approved for the treatment of several conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. This medication is intended for patients who have not adequately responded to standard therapies, providing them with a potential improvement in their symptoms and overall quality of life.
Before you buy Remsima, it is crucial that you talk to your healthcare provider about potential side effects and Remsima cost.
| Fact Table | |
|---|---|
| Generic Name | Infliximab |
| License | FDA and EMA approved |
| Bioavailability | 83% (after intravenous administration) |
| Legal Status | Prescription Drug |
| Brand Name | Remsima |
| Elimination Half-Life | 7.7 to 9.5 days |
| Dosage (Strength) | Varies by indication; typically 3 to 10 mg/kg |
| Pregnancy | B2 (Australia), C (USA), Not recommended |
| Protein Binding | Not significant |
| Routes of Administration | Intravenous infusion |
| DrugBank | DB00065 |
| KEGG | D02597 |
| ChEBI | 63516 |
| ATC Code | L04AB02 |
Remsima pen is administered as an intravenous (IV) infusion. The standard dose and schedule depend on the specific condition being treated:
For adults with rheumatoid arthritis or psoriatic arthritis: Remsima is usually given in combination with methotrexate. The typical schedule involves an initial dose, followed by additional doses at two weeks and six weeks after the first infusion, and then every eight weeks thereafter.
For Crohn's disease, ulcerative colitis, ankylosing spondylitis, and plaque psoriasis: The dosing schedule is similar, but the medication is often administered as a monotherapy.
The infusion process usually takes around two hours, and patients are monitored during and after the infusion for any adverse reactions.
The active ingredient in Remsima is infliximab.
Remsima can lower the ability of the immune system to fight infections.
Patients may experience allergic reactions to infliximab, ranging from mild rash to severe anaphylactic reactions.
There is an increased risk of lymphoma and other malignancies with the use of TNF blockers like Remsima. Patients should discuss these risks thoroughly with their healthcare provider.
Patients with heart failure should use Remsima with caution. Worsening of heart failure has been reported with TNF blockers, and in some cases, it has been fatal.
Remsima can interact with other medications, including other biologic DMARDs (Disease-Modifying Anti-Rheumatic Drugs) and live vaccines. Patients with a history of heart failure, neurological disorders, or chronic infections should use Remsima cautiously as it may exacerbate these conditions. Alcohol may increase the risk of liver problems and should be consumed in moderation.
Common Side Effects:
What does Remsima do?
Remsima (infliximab) is a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It works by targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a protein involved in inflammatory processes.
How long can Remsima be out of the fridge?
Remsima should be stored in a refrigerator at 2-8°C (36-46°F). If needed, it can be stored at room temperature up to 25°C (77°F) for a maximum of 6 months. After this period or if the medication has been out of the fridge for longer than the allowed time, it should not be used.
Is Remsima infliximab a biosimilar?
Yes, Remsima is a biosimilar to Remicade (infliximab). Biosimilars are highly similar to their reference biologic drugs in terms of safety, efficacy, and quality but may have minor differences in clinically inactive components.
How long is a Remsima infusion?
The infusion of Remsima typically takes about 2 hours. The first infusion may be given more slowly to monitor for any adverse reactions. Subsequent infusions can sometimes be administered more quickly, depending on the patient's tolerance and physician's discretion.
Is Remsima the same as Remicade?
Remsima is not exactly the same as Remicade, but it is a biosimilar to Remicade. This means it has no clinically meaningful differences from Remicade in terms of safety, purity, and potency, though it is not identical.
Where to inject Remsima?
Remsima is administered via intravenous (IV) infusion. It is not an injection given into the muscle or under the skin. The infusion is typically administered in a healthcare setting by a professional.
What is the protocol for Remsima?
The protocol for Remsima involves an initial dose followed by subsequent doses at specific intervals. Typically, patients receive an initial infusion, followed by additional infusions at 2 weeks and 6 weeks after the first dose. After that, infusions are usually given every 8 weeks. The exact protocol may vary based on the condition being treated and patient response.
What are the drug levels for Remsima?
Drug levels for Remsima (infliximab) can vary widely among patients. Therapeutic drug monitoring (TDM) is sometimes used to measure infliximab levels in the blood to ensure they are within the therapeutic range, optimizing treatment efficacy and minimizing side effects. Target trough levels can range from 3 to 7 µg/mL, though this can vary based on individual patient factors and specific disease indications.
When was Remsima approved?
Remsima was first approved in the European Union in 2013. It has since been approved in various countries, including the United States, where it received approval from the FDA in 2016 under the name Inflectra.
What are the side effects of Remsima infusion?
Common side effects of Remsima infusion include respiratory infections, headache, and abdominal pain. Serious side effects can include severe infections, infusion-related reactions, heart failure, liver damage, and reactivation of hepatitis B or tuberculosis. Patients should be closely monitored during and after the infusion for any adverse reactions.
